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Abstract
A subclass of patients with classic infantile autism have uric acid excretion which is s 2 S.D.s above the normal mean.
These hyperuricosuric autistic individuals may comprise approx. 20% of the autistic population. In order to determine the
metabolic basis for urate overexcretion in these patients, de novo purine synthesis was measured in the cultured skin
fibroblasts of these patients by quantification of the radiolabeled purine compounds produced by incubation with
radiolabeled sodium formate. For comparison, de novo purine synthesis in normal controls, in normouricosuric autistic
patients, and cells from patients with other disorders in which excessive uric acid excretion is seen was also measured. These
experiments showed that de novo purine synthesis is increased approx. 4-fold in the hyperuricosuric autistic patients. This
increase was less than that found in other hyperuricosuric disorders. No unusual radiolabeled compounds (such as
adenylosuccinate) were detected in these experiments, and no gross deficiencies of radiolabeled nucleotides were seen.
However, the ratio of adenine to guanine nucleotides produced by de novo synthesis was found to be lower in the cells of the
hyperuricosuric autistic patients than in the normal controls or the cells from patients with other disorders. These results
indicate that the hyperuricosuric subclass of autistic patients have increased de novo purine synthesis, and that the increase is
approximately that expected for the degree of urate overexcretion when compared to other hyperuricosuric disorders. No
particular enzyme defect was suggested by either gross deficiency of a radiolabeled compound or the appearance of an
unusual radiolabeled compound, and no potentially neurotoxic metabolites were seen. Although an enzyme defect
responsible for the accelerated purine synthesis was not identified, the abnormal ratio of adenine to guanine nucleotides
suggests a defect in purine nucleotide interconversion. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Given the number of well-de¢ned metabolic disor-
ders which are associated with behavioral and neuro-
logical abnormalities [1,2], it is reasonable that a
subset of patients with classic infantile autism might
have some metabolic disorder as the cause of their
autistic symptoms. Indeed, a number of patients with
phenylketonuria display classic autism [3,4]. Other
metabolic disorders, including adenylosuccinate lyase
de¢ciency [5], dihydropyrimidine dehydrogenase de-
¢ciency [6], histidinemia [7], and 5P-nucleotidase
superactivity [8] display autistic symptoms, but do
not ful¢ll the DSM-IV criteria [9] for classic infantile
autism.
A number of cases have been reported describing
patients with classic autistic symptoms combined
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with prominent hyperuricosuria [10^17]; although di-
agnosed before standardized diagnostic criteria were
established, many of these patients ful¢ll the DSM-
IV criteria for classic autism. A number of these
patients exhibited neurological symptoms as well, in-
cluding seizures, ataxia, and spasticity. Despite the
prominent increase in uric acid production, plasma
concentration of urate in most cases is within the
normal range, and there is no evidence of urate path-
ology such as gout or kidney stones. In some of these
reports the autistic and/or neurological symptoms
seem to have been ameliorated by antihyperuricosu-
ric metabolic therapy. Two patients [10,15] were ob-
served to bene¢t from a low purine diet, which de-
creased their purine excretion and made them more
alert and sociable. Two other patients [11,12] were
shown by double-blind crossover studies to have re-
duced seizures, less ataxia, and improved behavior
with the anti-gout drug allopurinol. Studies under-
taken to determine the percentage of the autistic
population which overproduces uric acid arrived at
a ¢gure of 11^28% [13,16,17] as compared to 0^3%
[16,18] of the non-autistic population. These were
clinic-based studies, not population-based epidemio-
logical surveys.
Two well-studied defects of purine metabolism
which are associated with uric acid overproduction
are hypoxanthine phosphoribosyltransferase (HPRT)
de¢ciency [19] and phosphoribosyl pyrophosphate
synthetase (PRPPS) superactivity [20]. In both of
these disorders it is possible to demonstrate increased
de novo purine synthesis, either by increased incor-
poration of radiolabeled glycine into uric acid in the
urine of a¡ected individuals or by increased incorpo-
ration of radiolabeled glycine or formate into purine
compounds in the cultured cells of patients. The
present study was undertaken to determine if in-
creased de novo purine synthesis could be demon-
strated in the cultured ¢broblasts of hyperuricosuric
autistic patients as well, and if so, to compare the
rate of purine synthesis with that of these other hy-
peruricosuric metabolic disorders. A second objective
was to detect any abnormal accumulation of inter-
mediates (such as succinylaminoimidazole carbox-
amide ribonucleotide) during de novo synthesis or
any abnormal distribution of purine compounds pro-
duced by de novo synthesis which might suggest an
enzyme defect.
2. Materials and methods
The subjects for this study were chosen for the
presence of both classic autistic symptoms and uric
acid production greater than 2 S.D.s above the nor-
mal mean.
The clinical presentation of nine patients is sum-
marized in Table 1. These patients were diagnosed
before the DSM-IV criteria were established; when
reevaluated all subjects ful¢lled the criteria for autis-
tic disorder [9]. All the patients exhibited typical au-
tistic symptoms, including lack of interest in social
contact, severely restricted communicative ability,
and lack of imaginative activity. In every case these
symptoms were apparent by the third year. Stereo-
typic behavior was seen in all patients and consisted
of twirling, repetitive motions, toe-walking, and
hand-£apping. Though accurate assessment of intel-
lectual capacity was complicated by impaired com-
municative ability, six of the nine patients were
judged to be mildly retarded, though two of these
retarded individuals were thought to have savant
skills. All showed some type of abnormal sensory
response, such as increased sensitivity to auditory
stimuli or decreased sensitivity to pain. Self-injurious
behavior was seen in four of the nine patients and
included eye-poking, head-banging, or hair-pulling.
Clinical seizures and abnormal EEGs were seen in
six of the nine patients and were of varied types.
As is often noted with hyperuricosuric autistic pa-
tients [16] dietary sensitivities were present; ingestion
of certain foods seemed to exacerbate both behavio-
ral and neurological symptoms. All patients were put
Table 1
Clinical features of hyperuricosuric autistic subjects
Symptom Patient
1 2 3 4 5 6 7 8 9
Early onset of symptoms + + + + + + + + +
Autistic aloneness + + + + + + + + +
Communication de¢cit + + + + + + + + +
Stereotypic behaviors + + + + + + + + +
Apparent mental retardation + + + 3 + 3 + 3 +
Abnormal sensory response + + + + + + + + +
Self-injurious behavior 3 + + 3 + + + + 3
Seizures + 3 3 + + + 3 + +
Savant skills + 3 3 3 + 3 3 + +
Dietary sensitivities + 3 + + 3 3 + + 3
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on the low purine diet between the ages of 3 and 8
(see below). Although all patients showed excessive
urate excretion by 24 h urate assay, all had normal
plasma urate values between 1.4 and 5.2 mg/dl.
Although 24 h urate values were not obtained for
the normal control subjects from whom the skin bi-
opsies were taken, the normal values for 24 h urate
excretion with respect to age and sex as well as the
rarity of excessive urate excretion in the normal pop-
ulation have been extensively studied and reported
previously [16,18].
14C-Sodium formate (55 mCi/mmol) was obtained
from Moravek Radiochemicals (Brea, CA, USA). All
other reagents were obtained from Sigma (St. Louis,
MO, USA).
Uric acid was measured by the uricase method on
a 24 h urine sample [21]. For the urine collection
patients and controls were not following any special
diet, nor were they receiving any medication.
Fibroblasts from punch biopsies were grown in
Coon’s F12 medium with 10% fetal bovine serum
(FBS) in 100 mm plates. Cells were harvested in
the log phase of growth between passages 6 and
10, replated at a density of 5U105 cells per plate
and switched to Earl’s MEM with 10% dialyzed
FBS. After 72 h, the cells were harvested, replated
at 106 cells per plate, and 7 ml of MEM containing
10 WCi 14C-sodium formate was added. Cells were
incubated for an additional 24 h and harvested by
trypsinization. The cell pellet was extracted with 0.8
M perchloric acid, precipitated protein and cell de-
bris were removed by centrifugation at 20 000Ug,
and the supernatant was neutralized to pH 5^7
with 2 M potassium phosphate bu¡er, pH 7.5. La-
beled and unlabeled purine bases, nucleosides, and
nucleotides were identi¢ed and quanti¢ed by HPLC
with continuous scintillation counting by the method
of Ryll and Wagner [22], in which all these com-
pounds are quanti¢ed in a single analysis. De novo
purine synthesis was calculated as nmol purine nu-
cleotides synthesized+radiolabeled purines excreted
into medium/100 nmol purines present in the cell/
24 h as previously described [23]. The adenine to
guanine nucleotide ratio was calculated from the
amounts of radiolabeled nucleotides as (AMP+
ADP+ATP)/(GMP+GDP+GTP). For each subject
three di¡erent incorporation experiments were per-
formed.
3. Results
The urate excretion and de novo purine synthesis
in the cultured ¢broblasts of the hyperuricosuric pa-
tients are shown in Table 2. For comparison, de
novo purine synthesis was measured by the same
method in the cultured ¢broblasts of normal con-
trols, two normouricosuric autistic patients, a Lesch-
Nyhan patient, a neurologically normal HPRT-de¢-
cient hyperuricosuric patient, and a patient with
PRPP synthetase superactivity. Owing to the di⁄-
culty of ¢nding age-matched normal control cell
lines, urate excretion was not measured in the indi-
viduals from whom these lines were established but is
assumed to be normal; instead, the literature average
normal value [16] is shown in Table 2.
Urate excretion was elevated approx. 2^3-fold in
the hyperuricosuric autistic subjects; de novo synthe-
sis in the ¢broblasts of these patients was found to be
elevated 3^4-fold; this increase was both consistent
and statistically signi¢cant (P6 0.01). Subjects with
other defects of purine metabolism showed both a
higher excretion of uric acid and a greater increase
in de novo purine synthesis. Two autistic subjects
with normal urate excretion had de novo purine syn-
thesis comparable to the normal controls.
All subjects produced both adenine and guanine
nucleotides from formate. No unusual radiolabeled
intermediates of the de novo pathway (such as suc-
cinylaminoimidazole carboxamide ribonucleotide) or
purine interconversion pathways (such as adenylo-
succinate) were seen in the cells of the hyperuricosu-
ric autistic subjects. Nor were any gross de¢ciencies
of labeled purine compounds which would suggest an
enzyme de¢ciency noted in these subjects. However,
careful analysis of the ratio of labeled adenine to
guanine nucleotides revealed that this ratio was on
average lower in the hyperuricosuric autistic subjects
than in the normal controls (Table 2). The nucleotide
ratios (AMP:ADP:ATP and GMP:GDP:GTP) did
not di¡er signi¢cantly from those of normal controls
(data not shown). The di¡erence in the adenine to
guanine ratio reached statistical signi¢cance
(P6 0.05) in the case of the hyperuricosuric autistic
subjects. In the case of the cells of the subject with
other defects of purine metabolism and in the cells
from the normouricemic autistic subjects this ratio
was comparable to normal controls. Although the
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conversion of radiolabeled IMP to adenine and gua-
nine nucleotides was abnormal in the cells of the
hyperuricosuric autistic cells, the steady-state concen-
tration of purine nucleotides was comparable to nor-
mal controls (data not shown).
4. Discussion
In the hyperuricosuric subclass of autistic patients,
urate excretion is elevated 2^3-fold compared to nor-
mal controls. A 3^4-fold increase in de novo purine
synthesis which accounts for this increased urate ex-
cretion can be demonstrated in the cultured skin ¢-
broblasts of these patients. An abnormal ratio of
adenine to guanine nucleotides synthesized by the
de novo pathway suggests that a defect in purine
nucleotide interconversion may be responsible for
the observed increased de novo purine synthesis.
In the cells of all the subjects with urate overpro-
duction, a roughly proportionate increase in de novo
purine synthesis was noted. Most elevated were the
HPRT-de¢cient patients, with a nearly 5-fold in-
crease in purine excretion and a more than 6-fold
increase in de novo purine synthesis. These increases
have been found to be typical of HPRT-de¢cient
patients [19]. A somewhat smaller elevation in both
urate excretion and de novo purine synthesis is found
in subjects with PRPP synthetase superactivity [20].
Both HPRT-de¢cient and PRPP synthetase superac-
tive subjects typically have elevated plasma urate
[19,20]. These individuals often experience the patho-
logical consequences of urate overproduction, includ-
ing gout and kidney stones.
The hyperuricosuric autistic subjects appear to
have a more modest 2^3-fold increase in urate pro-
duction and 3^4-fold increase in de novo purine syn-
thesis, as measured in their cultured ¢broblasts.
These individuals do not usually have elevated plas-
ma uric acid, and rarely experience any type of urate
pathology. Apparently, removal of urate by the kid-
neys is adequate in the case of this smaller increase.
The relationship between urate overproduction
and the autistic symptomatology seen in the hyper-
uricosuric subclass of autism is unlikely to be a direct
one, despite circumstantial evidence linking the two.
Table 2
Urate excretion and de novo purine synthesis
Subject Age
(years)
Urate excretion
(mg urate/kg/day)
De novo purine synthesis
(nmol/100 nmol/24 h)
Adenine/guanine
nucleotide ratio
NC 1 12 (8.3 þ 2.0) 8.238 þ 6.47 6.47
NC 2 4 (8.3 þ 2.0) 10.907 þ 7.41 7.41
NC 3 6 (8.3 þ 2.0) 8.701 þ 7.96 7.97
NC 4 3 (8.3 þ 2.0) 10.105 þ 6.29 6.29
NC 5 7 (8.3 þ 2.0) 6.929 þ 7.62 7.62
8.976 þ 1.56 7.15 þ 0.73
HA 1 5 26.5 28.588 þ 3.264 4.14
HA 2 7 19.8 34.531 þ 3.819 4.42
HA 3 12 17.9 34.528 þ 3.754 4.04
HA 4 4 16.2 34.935 þ 0.637 5.67
HA 5 5 35.4 34.258 þ 3.784 6.38
HA 6 9 18.1 34.448 þ 6.918 4.65
HA 7 4 14.7 23.756 þ 1.879 5.87
HA 8 10 17.9 32.018 þ 2.502 6.71
HA 9 3 22.4 38.429 þ 2.825 6.41
32.832 þ 4.289 5.36 þ 1.0
NA 1 6 5.9 8.348 þ 0.715 7.23
NA 2 4 8.7 6.254 þ 0.284 6.69
PRPPS superactivity 3 43 49.374 þ 1.858 8.66
HPRT de¢ciency gout 4 37 54.916 þ 3.360 6.53
Lesch-Nyhan 6 48 61.141 þ 1.336 5.76
NC, normal control ; HA, hyperuricosuric autistic ; NA, normouricosuric autistic. The adenine/guanine nucleotide ratio was calculated
as (AMP+ADP+ATP)/(GMP+GDP+GTP).
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Some of these patients bene¢t from allopurinol, a
xanthine oxidase inhibitor which decreases produc-
tion of xanthine and uric acid; allopurinol was found
to decrease seizures and improve learning and atten-
tion in some patients [11,12]. Several of the hyper-
uricosuric autistic patients [10,15] were also observed
to bene¢t from a low purine diet [24] which also
lowers urate excretion. Although it is di⁄cult to ac-
count for placebo e¡ects in experimental diets, dra-
matic improvement is seen occasionally. The patient
reported by Hooft [10] was said to have ‘an undeni-
able improvement’ in both behavioral and neurolog-
ical symptoms. However, no crossover phase was
reported. In another case [15] the hyperuricosuric
autistic subject showed improvements in speech, at-
tention, and social interaction on a low purine diet; a
trial at replacement of the low purine diet with a
high purine diet resulted in extreme hyperactivity
and decreased social interaction within 2 days. Re-
instatement of the low purine diet restored the sub-
ject to her pretrial condition. These ¢ndings might
suggest that uric acid itself may be responsible for
autistic and/or neurological symptoms. Although
some patients with HPRT de¢ciency and PRPP syn-
thetase superactivity do show a variety of behavioral
and neurological symptoms, these symptoms show
no similarity to autism. Some of these patients
have uric acid overproduction greater than that
seen in the hyperuricosuric autistic patients and no
neurological or behavioral symptoms whatsoever.
Glycogen storage disease type I (glucose 6-phospha-
tase de¢ciency) is another disorder with urate over-
production similar to that of the patients described
here, but with no neurological or behavioral symp-
toms [25].
The exact enzyme defect responsible for increased
de novo purine synthesis in purine autism is thus far
not known, but the ¢nding of an abnormal adenine/
guanine nucleotide ratio in these patients suggests
that it is one of the enzymes of purine nucleotide
interconversion. Experimental models of defects in
purine nucleotide interconversion are known to pro-
duce both increased de novo purine synthesis and
increased purine excretion [26,27]. These models in-
clude decreased adenylosuccinate synthetase, de-
creased IMP dehydrogenase, and greatly increased
IMP dehydrogenase. In each case, the conversion
of IMP to adenine and guanine nucleotides is abnor-
mal although the steady-state concentration of nu-
cleotides is normal. This ¢nding is typical of cells
of patients with severe de¢ciencies in one of the en-
zymes of purine metabolism, such as HPRT3 cells ;
although incorporation of hypoxanthine into purine
nucleotides is grossly abnormal, steady-state concen-
trations of nucleotides are normal [19]. In at least
one case [28], an abnormality of purine nucleotide
interconversion was shown to result in clinical
gout; in this case a mutant liver AMP deaminase
was found to be insensitive to inhibition by GTP,
resulting in increased adenine nucleotide catabolism
and increased de novo purine synthesis.
Unlike the case of adenylosuccinate lyase de¢-
ciency, in which large quantities of potentially neuro-
toxic substances are produced, here, there is no ob-
vious relationship between increased de novo
synthesis or altered nucleotide interconversion and
autistic symptoms; knowledge of the enzyme defect
and its metabolic consequences in hyperuricosuric
autism might shed some light on this relationship
and perhaps aid in the design of a rational metabolic
therapy. These patients seem amenable to metabolic
therapy; if the enzyme defect were known and its
metabolic consequences better understood it might
be possible with purine dietary supplements to re-
verse these consequences and bring about improve-
ment of their autistic symptoms.
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